Winners and Losers of the Fed's Latest Bank Stress Test

Michael Teague  |

The results of the Federal Reserve’s second round of stress tests for 18 banks were released on Thursday afternoon, with almost no surprises.

American Express (AXP), Bank of America (BAC), the Bank of New York (BK), Capital One (COF), Citigroup (C), Fifth Third Bank Corp (FITB), KeyCorp (KEY), Morgan Stanley (MS), PNC Financial Services Group (PNC), Regions Financial Corp. (RF), State Street Corp. (STT), Sun Trust Banks (STI), US Bancorp (USB) and Wells Fargo (WFC) will surely be happy to be able to announce dividend payouts and share buybacks to their shareholders as soon as possible.  Many of them already have.

Ally Financial’s original plan was rejected last week, and so it is not entirely surprising that this was also the case with their revised plan.  According to the Fed, the bank’s capital ratios would not meet requirements in a worst-case-scenario, nor was its capital planning process found to be sufficient.

BB&T's (BBT) rejection by the fed was much more of a surprise.  Though the bank’s capital met the Fed’s threshold requirements, their dividend payout and stock buyback plans were sent back based on problems with the capital planning process.  The Fed has not explained this decision, but the bank itself has said only that it would have to reconsider “unfunded lending commitments” in order to meet with regulatory requirements.

J.P. Morgan Chase (JPM) and Goldman Sachs (GS) passed, sort of, but must retool their share distribution plans by the end of the third quarter.  In the meantime, their plans were given “conditional approval”, according to a senior Fed official.  Failure to resubmit the plans, however, could result in them ultimately being rejected.

In afterhours trading, J.P. Morgan’s shares dipped 1.92 percent to $50.02, while Goldman’s were down 1.77 percent to 151.30.  BB&T lost just over 3 percent, to $30.77.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
PNC PNC Financial Services Group Inc. (The) 124.39 -0.19 -0.15 1,993,539 Trade
KEY KeyCorp 16.89 -0.01 -0.06 11,093,341 Trade
C Citigroup Inc. 62.13 0.28 0.45 16,817,952 Trade
FITB Fifth Third Bancorp 27.57 0.01 0.04 4,660,326 Trade
MS Morgan Stanley 42.15 -0.26 -0.61 15,582,849 Trade
AXP American Express Company 99.71 -0.12 -0.12 3,585,120 Trade
AGO.P.B Assured Guaranty Ltd. 25.84 0.04 0.14 1,254 Trade
GS Goldman Sachs Group Inc. (The) 196.90 -0.78 -0.39 3,409,876 Trade
BBT BB&T Corporation 49.41 0.27 0.55 6,470,340 Trade
BAC Bank of America Corporation 28.92 -0.17 -0.58 79,403,313 Trade
COF Capital One Financial Corporation 78.20 -5.20 -6.24 8,586,280 Trade
USB U.S. Bancorp 50.53 0.39 0.78 7,785,087 Trade
BK Bank of New York Mellon Corporation (The) 53.06 0.47 0.89 6,233,170 Trade
RF Regions Financial Corporation 15.37 -0.22 -1.41 12,494,856 Trade
WFC Wells Fargo & Company 50.12 0.26 0.52 16,804,071 Trade
STI SunTrust Banks Inc. 60.56 0.20 0.33 3,448,126 Trade
JPM JP Morgan Chase & Co. 102.68 -0.26 -0.25 12,145,928 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…